TACROLIMUS
Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM cohort.
Same molecule, other indications
TACROLIMUS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →